EMAIL TO A FRIEND COMMENT

 

New Treatment for Adult Acute Lymphoblastic Leukemia Approved


On August 17, 2017, the FDA approved Besponsa (inotuzumab ozogamicin) for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL).

 

“For adult patients with B-cell ALL whose cancer has not responded to initial treatment or has returned after treatment, life expectancy is typically low,” said Richard Pazdur, M.D., director of the FDA’s Oncology Center of Excellence and acting director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “These patients have few treatments available and today’s approval provides a new, targeted treatment option.”

 

B-cell precursor ALL is a rapidly progressing type of cancer in which the bone marrow makes too many B-cell lymphocytes, an immature type of white blood cell. The National Cancer Institute estimates that approximately 5,970 people in the United States will be diagnosed with ALL this year and approximately 1,440 will die from the disease.

 

Besponsa is a targeted therapy that is thought to work by binding to B-cell ALL cancer cells that express the CD22 antigen, blocking the growth of cancerous cells.

 

The safety and efficacy of Besponsa were studied in a randomized trial that measured the percentage of patients with no evidence of disease and full recovery of blood counts after treatment (complete remission). Of the 218 evaluated patients, 35.8 percent who received Besponsa experienced complete remission for a median 8.0 months. Of the patients who received alternative chemotherapy, 17.4 percent experienced complete remission for a median 4.9 months.

 

Common side effects of Besponsa include low levels of platelets (thrombocytopenia), low levels of certain white blood cells (neutropenia, leukopenia), infection, low levels of red blood cells (anemia), fatigue, severe bleeding (hemorrhage), fever (pyrexia), nausea, headache, low levels of white blood cells with fever (febrile neutropenia), liver damage (transaminases and/or gamma-glutamyltransferase increased), abdominal pain, and high levels of bilirubin in the blood (hyperbilirubinemia).

 

The prescribing information for Besponsa includes a boxed warning that severe liver damage (hepatotoxicity), including blockage of veins in the liver (veno-occlusive disease [VOD] or sinusoidal obstruction syndrome), occurred in some patients who took Besponsa. The boxed warning also includes an increased risk of death for patients who take Besponsa after receiving a certain type of stem cell transplant.

 

Other serious side effects of Besponsa include a decrease in blood cell and platelet production (myelosuppression), infusion-related reactions, and problems with the heart’s electrical pulses (QT interval prolongation). Women who are pregnant or breastfeeding should not take Besponsa because it may cause harm to a developing fetus or a newborn baby.

 

See the FDA Announcement

 

See also Medical Law Perspectives Report: Chemotherapy: Risks and Liabilities When the Treatment Is Toxic

 

See also Medical Law Perspectives Report: Drugs, Dosage, and Damage: Physician Liability for Prescribing or Administering Medication

 

 

REPRINTS & PERMISSIONS COMMENT